These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 16669974)

  • 1. Optimal care of autosomal dominant polycystic kidney disease patients.
    Schrier RW
    Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Schrier RW
    J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
    Masoumi A; Elhassan E; Schrier RW
    Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension and left ventricular hypertrophy in autosomal dominant polycystic kidney disease.
    Ecder T; Schrier RW
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):369-74. PubMed ID: 15151483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
    Lawson CR; Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autosomal dominant polycystic kidney disease: clinical and genetic aspects.
    Sessa A; Ghiggeri GM; Turco AE
    J Nephrol; 1997; 10(6):295-310. PubMed ID: 9442442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic interventions for autosomal dominant polycystic kidney disease.
    Edelstein CL
    Nephrol News Issues; 2008 Mar; 22(3):25-6. PubMed ID: 18372677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Ulusoy S; Ozkan G; Orem C; Kaynar K; Koşucu P; Kiriş A
    Ren Fail; 2010; 32(8):913-7. PubMed ID: 20722556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
    Tkachenko O; Helal I; Shchekochikhin D; Schrier RW
    Curr Hypertens Rev; 2013 Feb; 9(1):12-20. PubMed ID: 23971639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
    Zafar I; Tao Y; Falk S; McFann K; Schrier RW; Edelstein CL
    Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ADPKD and Heart].
    Liut F; Izzi C; Dallera N; Scolari F
    G Ital Nefrol; 2017 Mar; 34(Suppl 69):119-130. PubMed ID: 28682033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension in autosomal dominant polycystic kidney disease: observational study in 207 patients with a mean follow-up of 107 months.
    De Almeida EA; Prata MM
    Rev Port Cardiol; 2007 Nov; 26(11):1173-82. PubMed ID: 18297839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiovascular risk in polycystic kidney disease].
    Di Lorenzo A; Stallone G; Infante B; Grandaliano G; Schena FP
    G Ital Cardiol (Rome); 2015 Sep; 16(9):479-84. PubMed ID: 26418387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
    Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
    Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD).
    Cadnapaphornchai MA; Fick-Brosnahan GM; Duley I; Johnson AM; Strain JD; DeGroff CG; Schrier RW
    Contemp Clin Trials; 2005 Apr; 26(2):211-22. PubMed ID: 15837441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population.
    Kelleher CL; McFann KK; Johnson AM; Schrier RW
    Am J Hypertens; 2004 Nov; 17(11 Pt 1):1029-34. PubMed ID: 15533729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable renal disease progression in autosomal dominant polycystic kidney disease: a role for nitric oxide?
    Devuyst O
    J Nephrol; 2003; 16(3):449-52. PubMed ID: 12832751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New therapies for ADPKD].
    Rathaus M
    G Ital Nefrol; 2007; 24(6):526-34. PubMed ID: 18278756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T; Edelstein CL; Chapman AB; Johnson AM; Tison L; Gill EA; Brosnahan GM; Schrier RW
    Nephrol Dial Transplant; 1999 May; 14(5):1113-6. PubMed ID: 10344347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.